The Clinical Trials Support Resource (CTSR) provides infrastructure support for all aspects of clinical protocol research at MD Anderson. The services of this shared resource encompass submitting, activating, and closing single and multi-centered clinical trials;educating research staff on human subjects/clinical research;auditing and monitoring active clinical trials;and ensuring regulatory compliance of IND studies. The online data management system is maintained by the CTSR. The CTSR complements the activities of the Protocol Review and Monitoring System by supporting the electronic protocol submission and review processes, and the CTSR will manage the transition from the current electronic protocol management system to a new platform called """"""""research,"""""""" which will """"""""go live"""""""" in early 2013. The CTSR is supported by 106 staff members (of which 8 full-time employees receive full or partial support from the CCSG) under the direction of Dr. Aman Buzdar, Vice President for Clinical Research Administration. During the past 5 years, the number of new protocols managed by CTSR has increased by 4% from 4,632 in fiscal year (FY) 2007 to 4,818 in FY 2011. Overall, trials led by MD Anderson investigators contributed to the FDA approval of 19 drugs for initial or new indications. New patient registrations have increased from 28,762 in FY 2007 to 46,262 in FY 2011, and the number of patients enrolled in therapeutic clinical trials has increased by 18%, from 6,219 in FY 2007 to 7,558 in FY 2011. During the last grant year, the funds used to support the CTSR salaries were $442,190 (9%) from the CCSG, $812,112 (16%) from user fees, and $3,742,322 (75%) from MD Anderson. In the next award cycle, the level of support from the CCSG, user fees, and MD Anderson is projected to be closer to 4%, 7%, and 89%, respectively. During this past 5-year funding period, CTSR resources were used by 934 principal investigators affiliated with all 19 CCSG programs. Peer reviewed investigators account for 61% of the utilization and 4% of total costs are requested from the CCSG. Publications cited using the CTSR have appeared in several high impact journals such as N Engl J Med and J Clin Oncol. Future plans include implementation of research, which will serve as the new institutional clinical data enterprise system;coordination and modification of inter-departmental operational processes to further reduce time from submission to activation of clinical trials to 60 days;and further enhancements to the human subjects protection training programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016672-38
Application #
8557386
Study Section
Subcommittee G - Education (NCI)
Project Start
1998-09-04
Project End
2018-06-30
Budget Start
2013-09-06
Budget End
2014-06-30
Support Year
38
Fiscal Year
2013
Total Cost
$600,170
Indirect Cost
$225,136
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Van Roosbroeck, Katrien; Fanini, Francesca; Setoyama, Tetsuro et al. (2016) Combining anti-miR-155 with chemotherapy for the treatment of lung cancers. Clin Cancer Res :
Cassani, Lisa S; Raju, Gottumukkala S (2016) Techniques for management of bleeding associated with colonic endoscopic mucosal resection. Gastrointest Endosc 83:469-70
Zargar, Homayoun; Atwell, Thomas D; Cadeddu, Jeffrey A et al. (2016) Cryoablation for Small Renal Masses: Selection Criteria, Complications, and Functional and Oncologic Results. Eur Urol 69:116-28
Ma, Junsheng; Hobbs, Brian P; Stingo, Francesco C (2016) Integrating genomic signatures for treatment selection with Bayesian predictive failure time models. Stat Methods Med Res :
Jinesh, Goodwin G; Kamat, Ashish M (2016) Endocytosis and serpentine filopodia drive blebbishield-mediated resurrection of apoptotic cancer stem cells. Cell Death Discov 2:
Maiti, Abhishek; Cortes, Jorge E; Brown, Yolanda D et al. (2016) Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors. Leuk Lymphoma :1-4
Visone, R; Pallante, P; Vecchione, A et al. (2016) Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 35:5214
Zhou, Fuling; Li, Ming; Wei, Yongchang et al. (2016) Activation of HERV-K Env protein is essential for tumorigenesis and metastasis of breast cancer cells. Oncotarget :
Gamaletsou, Maria N; Rammaert, Blandine; Bueno, Marimelle A et al. (2016) Candida Arthritis: Analysis of 112 Pediatric and Adult Cases. Open Forum Infect Dis 3:ofv207
Parra, Edwin R; Behrens, Carmen; Rodriguez-Canales, Jaime et al. (2016) Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients. Clin Cancer Res :

Showing the most recent 10 out of 9121 publications